Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

tolerability profile

7 posts
RRoche
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Read More

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

  • 2026-06-08
F. Hoffmann-La Roche Ltd Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to…
RRoche
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Read More

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

  • 2026-06-01
F. Hoffmann-La Roche Ltd Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to…
RRoche
Will The Market Correct The Share Price In The Future?
Read More

Roche Petrelintide Data Recasts Obesity Opportunity And Pipeline Growth Story

  • 2026-03-23
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

  • 2026-03-08
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

  • 2026-03-06
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
RRoche
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
Read More

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

  • 2026-03-05
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Read More

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

  • 2026-02-15
F. Hoffmann-La Roche Ltd A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of…
Switzerland
www.europesays.com